依达拉奉联合舒血宁治疗脑梗死的系统评价

Edaravone Combined with Shuxuening for Cerebral Infarction: A Systematic Review

目的系统评价依达拉奉联合舒血宁治疗脑梗死的疗效和安全性。方法计算机检Cochrane图书馆、PubMed、EMbase、中国生物医学文献数据库、中国期刊全文数据库、维普数据库,检索时限均从建库起截止2013年3月31日,根据Cochrane系统评价方法对纳入的随机对照试验进行方法学质量评价,并用RevMan 5.0软件进行Meta分析。结果共纳入17个随机对照试验,研究结果显示:依达拉奉联合舒血宁组在总有效率、改善患者神经功能方面均优于对照组(P<0.05),不良反应发生率差异无统计学意义(P>0.05)。结论依达拉奉联用舒血宁治疗脑梗死有效,但纳入试验质量均较低,该结论还需高质量、大样本的研究进一步验证。

Objective To evaluate the effects and safety of edaravone combined with shuxuening for cerebral infarction. Methods The Cochrane Library, PubMed, EMbase, CBM, CNKI and VIP databases were searched from their establishments up to March 31, 2013. We used the method recommended by the Cochrane collaboration to perform a meta- analysis of randomized controlled trails （RCTs） with RevMan 5.0 software. Results Seventeen studies were included. The results of Meta-analysis demonstrated that edaravone combined with shuxuening were more efficient in reducing the score of neural function deficient scale and higher in the total effective rate （P 〈 0.05）, while there was no difference in the incidence of adverse reactions （P 〉 0.05）. Conclusion The study suggests that edaravone combined with shuxuening is effective for cerebral infarction, but it also needs further studies to provide more sufficient evidence.